Efficacy of CAR T cell therapy in large tumors relies upon stromal targeting by IFNγ

Ana Textor1, Joanna J. Listopad1, Lara Le Wührmann1, Cynthia Perez1†, Anna Kruschinski1, Markus Chmielewski2, Hinrich Abken2, Thomas Blankenstein1,3, and Jehad Charo1†

Authors’ Affiliations

1Max-Delbrück-Center for Molecular Medicine, 13092 Berlin, Germany
2Department I of Internal Medicine, Tumor Genetics, and Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany
3Institute of Immunology, Charite Campus Buch, 13092 Berlin, Germany
†Present address: Oncology Research Institute, Loyola University Chicago, Maywood IL 60153, Chicago, USA

Running Title

Chimeric Antigen Receptors Reject Solid Tumors

Corresponding Author

Jehad Charo, Oncology Research Institute, Loyola University Chicago, Cardinal Bernardin Cancer Center, 216 S. First Avenue, Room 304, Maywood, IL 60153, Tel. (708) 327-3325, Fax. (708) 327-3158, e-mail: jecharo@lumc.edu

Disclosure of Potential Conflicts of Interest

The authors have no conflicting financial interests.

Keywords: Chimeric Antigen Receptor, Solid tumor, Adoptive T cell Therapy, IFNγ

Abstract
Adoptive T cell therapy using chimeric antigen receptor-modified T cells (CAR-T therapy) has shown dramatic efficacy in patients with circulating lymphoma. However, eradication of solid tumors with CAR-T therapy has not been reported yet to be efficacious. In solid tumors, stroma destruction, due to MHC-restricted cross-presentation of tumor antigens to T cells, may be essential. However, CAR-Ts recognize antigens in an MHC-independent manner on cancer cells but not stroma cells. In this report, we show how CAR-Ts can be engineered to eradicate large established tumors with provision of a suitable CD28 costimulatory signal. In a HER-2-dependent tumor model, tumor rejection by HER-2-specific CAR-Ts was associated with sustained influx and proliferation of the adoptively transferred T cells. Interestingly, tumor rejection did not involve NK cells, but was associated instead with a marked increase in the level of M1 macrophages and a requirement for IFNγ receptor expression on tumor stroma cells. Our results argue that CAR-T therapy is capable of eradicating solid tumors through a combination of antigen-independent stroma destruction and antigen-specific tumor cell targeting.

**Precis**

This preclinical study shows how the inability of engineered T cell therapies to eradicate solid tumors can be overcome by enabling antigen-independent stroma destruction along with antigen-specific tumor cell targeting, providing possible insights into how to dramatically expand the use of these therapies beyond circulating blood tumors where they are currently useful.
Introduction

T cells can be redirected with new antigen specificity and used for adoptive T cell therapy (ATT) by introducing either a T cell receptor (TCR), or chimeric antigen receptor (CARs). The CAR consists of an antigen (Ag)-binding single chain variable fragment (scFv) antibody domain and a signaling domain, most often the CD3ζ endodomain (1). While T cells with CARs (CAR-Ts) containing CD3ζ had a moderate anti-tumor effect and poor persistence in vivo (2), addition of costimulatory signals as provided by dual signaling domains (e.g. CD28-CD3ζ) has improved the therapeutic effects of CAR-Ts in experimental models (3) and in clinical trials targeting CD19 on B cell malignancies (4,5).

Tumor transplantation models can be of clinical relevance if large established tumors grown for at least two weeks are treated (6). Such solid tumors are difficult to reject, but can be successfully eradicated if the target antigen is recognized through the TCR (7-11). On the other hand, CAR-mediated recognition leads to regression but not complete eradication (3). This could be due to the sub-optimal affinity of the CAR to the target antigen or the different mode of antigen recognition of CARs versus TCRs. In contrast to TCRs, which recognize peptide antigen presented by MHC class I (MHC I), CARs recognize the cognate cell surface antigen by an antibody domain independently of the MHC I. This can be an advantage since tumors escape TCR-mediated ATT by MHC I down-regulation (12), but it can also be a disadvantage because tumor stroma cells cross-presenting surrogate tumor antigen on MHC I needs to be recognized by T cells in order to prevent tumor escape (7). However, it appears that direct recognition of the tumor stroma is less important for tumor rejection if cancer-driving antigens (CDAs) are targeted by TCR-mediated ATT (10,11). CDAs are arguably the best targets because cancer cell proliferation/survival often depends on its continuous expression, as is the case for the human cell line SKOV3 and HER-2 (epidermal growth factor receptor-2) (13), which is termed oncogene addiction (14). HER-2 is normally an overexpressed self-antigen, but in
this study we utilized a mouse model where human HER-2 was expressed only on the SKOV3 tumor cells and not on mouse cells, which makes it a relevant model for tumor-specific antigens targetable by CAR-Ts (e.g. mutant epidermal growth factor receptor (EGFRvIII) or the chaperon Cosmc) (15,16).

Previous studies employing CARs for treatment of xenografted solid human tumors used polyclonal human T cells as recipient cells for the CAR (3,17), a model containing several confounding factors (Supplementary Fig. S1). Human CAR-Ts were allogeneic with regard to the tumor and xenogeneic with regard to the host. In this setting, it is difficult to exclude allo-MHC T cell responses (through the TCR) contributing to therapy effects. Conversely, lack of overt graft-versus-host reactions to the xenogeneic mouse tissues indicates that human T cells perform poorly in mice. An unknown number of species-specific factors necessary for survival and proliferation may impair the function of human T cells in mice. For example, IFNγ function is species-specific (18), so that human T cell-derived IFNγ cannot act on mouse tumor stroma cells, which had been shown in syngeneic models to be critical in order to prevent tumor recurrence (8,11). To avoid confounding factors with polyclonal human T cells in mice and better dissect the mechanism of tumor eradication by CAR-Ts, we used mouse monoclonal CD8+ T cells with tumor-unrelated specificity as CAR recipients (OVA-specific OT-1 cells derived from Rag-/- mice). This ensured that the CAR-Ts could act only through their CAR but not TCR, that IFNγ could act on the tumor stroma but not the human cancer cells and also excluded a potential contribution of CD4+ T cells on the therapeutic outcome (Supplementary Fig. S1). Here, we first established that eradication of large established tumors can be achieved by HER-2-specific CAR-Ts if provided with costimulatory CD28 signaling (28-ζ-CAR) (19). This rejection was associated with sustained accumulation, proliferation and differentiation of CAR-Ts to effector memory (TEM) cell type at the tumor site. We finally demonstrated that tumor
rejection by CAR-Ts involved destruction of tumor stroma through IFNγR,
independently of NK cell contribution.

**Materials and Methods**

**Mice**

All mouse studies were in accordance with institutional, state, and federal (Landesamt für Arbeitsschutz, Gesundheitsschutz und technische Sicherheit, Berlin) guidelines. Albino Rag1<sup>−/−</sup> or Rag2<sup>−/−</sup> (Rag<sup>−/−</sup>) mice, OT-1/Rag1<sup>−/−</sup> and ChRLuc/OT-1/Rag<sup>−/−</sup> mice were recently described (9). IFNγR<sup>−/−</sup> and Fas<sup>−/−</sup> mice were obtained from Jackson Laboratory (003288 and 000482, respectively) and bred at the MDC animal facility to Rag1<sup>−/−</sup> mice to obtain IFNγR<sup>−/−</sup>/Rag1<sup>−/−</sup> and Fas<sup>−/−</sup>/Rag1<sup>−/−</sup> mice.

**Retroviral vectors and cells**

HER-2 specific ζ-CARs constructs with scFv of different affinities and the 9-28-ζ-CAR of the intermediate affinity (20) were introduced into the MSCV expression plasmid as earlier described (21). pMSCV vector encoding for GFP (pMIG) was used as mock control. Retroviral supernatants were generated by cotransfecting HEK-T cells with different MSCV-CAR constructs and gag, pol and env encoding pCL-eco vector (Imgenex) as described previously (21). Virus supernatants were collected 48 and 72h post transfection and used for transducing T cells. Human ovarian carcinoma cell line SKOV3 expressing CBG luciferase was described earlier (21). It was authenticated by flow cytometry as described below.

**Expansion of T cells and retroviral transduction**

Spleens were isolated from OT-1/Rag<sup>−/−</sup> or ChRLuc/OT-1/Rag<sup>−/−</sup> mice and prepared as a single cell suspension with 0.8% NH₄Cl mediated lysis of red blood cells. 1-2x10⁵ cells were cultured in 24 well plates in 1 ml of complemented RPMI media (10% FCS, PAN Biotech; 50 μg/ml gentamicin, Gibco; and 50 μM mercaptoethanol, Gibco),
supplemented with 1 μg/ml anti (a)-CD3, 0.1 μg/ml a-CD28 antibody (Ab) (BD Bioscience) and 10 IU/ml IL-2 (Proleukin, Prometheus Laboratories) for 24h at 37°C in 5% CO₂ humidified incubator. Virus supernatants of different CAR constructs and mock control produced by HEK-T cells were collected, filtered (0.45 μm pore size) and either used directly for transduction or stored at -80°C. After 24h activation, media was removed from the splenocytes and replaced with 1 ml/well virus supernatant containing 10 μg/ml polybrene (Sigma-Aldrich). The cells were spinoculated for 2h at 800xg and 32°C. Virus supernatant was removed and replaced with 1 ml RPMI containing 10 IU IL-2. Cells were transduced twice, with an interval of 24h. The level of surface CAR expression was measured 24 or 48h after the last transduction.

**Flow cytometry**

Surface expression of the CARs was measured by staining with the F(ab)2 fragment from goat anti-human Ig polyclonal Ab conjugated to PE, APC or Dylight 649 (Southern Biotech or Jackson). Additionally cells were stained with a-CD8-APC (or FITC) (clone 53-6.7, BD Bioscience) and a-CD3-FITC Ab (clone G4.18, BD Bioscience). CAR-Ts were also analyzed for activation markers using a-CD44-FITC (clone IM7, BD Bioscience) and a-CD62L-PE (clone MEL-14, BD Bioscience), and for proliferation markers by a-KI-67 (Alexa Flour 488 clone B56, BD Bioscience) and Propidium Iodide staining Solution (BD Bioscience). NK cells were analyzed using a-NK1.1-APC (clone PK136, Biolegend) and a-CD49b-PE (pan-NK-cells, clone DX5, Biolegend) Ab. Macrophages were identified using a-F480-BV421 (clone BM8, Biolegend), a-CD11b-PE (clone M1/70, Biolegend) and additionally stained with a-IA-IE-PeCy7 (clone M5/114.15.2, Biolegend). Tumor samples were additionally analyzed by a-CD45.2-APC (clone 104, Biolegend) and a-Her2neu-PE (clone Neu 24.7, BD Bioscience) Ab. SKOV3 cells were stained with a-Her2neu-PE and with a-HLA-ABC (clone G46-2.6, BD Bioscience) as described earlier to confirm the species
origin and HER-2 expression (21). Data acquisition was performed on a FACS Calibur (BD Biosciences), MACSquant (Miltenyi Biotec) or FACSCanto (BD Biosciences), and the analysis was done by FlowJo (Tree Star) software.

**Tumor digestion and cytokine release assay**

A third or a half of the isolated tumor was sliced into small pieces and incubated for 1 hour at 37°C in 10 ml digestion solution (complete RPMI medium with collagenase II (1 mg/ml, Gibco), Dispase II (1 mg/ml, Roche) and DNAse I (10 μg/ml, Roche). Tumor cells were passed through a cell strainer (40 μm), washed with PBS and treated with ACK lysis buffer. Counted cells were prepared for flow cytometry analysis by incubation with a-FC receptor Ab (TruStain fcX, Biolegend) for 15 min at 4°C. CD8 T cells were purified from tumor cells by using a-CD8a (Ly-2) Microbeads (Miltenyi Biotec) according to the manufacturer’s protocol.

To measure cytokine release, CAR-Ts were mixed with mock transduced T cells to equalize the CAR⁺ cells between the different constructs in total of 2x10⁵ cells per construct, from which 1x10⁴ were CAR⁺. The CAR-Ts were then cocultured with titrated numbers of target SKOV3 tumor cells in 96-well flat bottom plates and 24-48h later IFNγ and IL-2 levels were measured in the supernatants by ELISA (BD Biosciences) according to the manufacturer’s protocol.

**Tumor challenge and adoptive T cell transfer**

Age and sex matched mice were injected with 5x10⁶ SKOV3-CBG tumor cells subcutaneously. On the day of treatment mice received i.v. injection of (unless otherwise indicated) 2x10⁶ CAR-Ts or mock T cells, resuspended in 100 μl PBS. Tumor size was measured by an electronic caliper and the average tumor diameter was calculated from the measurements of length, width and the depth of the tumor (9). Mice were sacrificed when the tumors reached 15 mm in any one dimension. To confirm the complete tumor rejection, at the end of the treatment experiments (at least 60 days after no palpable tumor was detected), tumor free mice were imaged.
for CBG luciferase signal emitted by any potentially remaining SKOV3 cells as described (21). NK cell depletion was achieved by weekly i.p. injection of 160 μg/mouse of a-NK1.1 Ab (clone PK136, BioXCell) or isotype control (IgG2a, BioXCell) throughout the experiment. NK cell depletion was confirmed several times over the time-course of the experiment. Tumor free mice from this experiment were observed for at least one week following tumor rejection and the rejection was confirmed by BLI.

Bioluminescence imaging

In vivo imaging was performed using a Xenogen IVIS 200 (Caliper Lifescience). A maximum of five anaesthetized mice were imaged at once. Each mouse received an i.v. injection of freshly prepared coelenterazine (Biosynth) that was dissolved in DMSO (Sigma) and diluted in PBS (100 μg/100 μl per mouse) as earlier described (9). Images were acquired for 1 min using small binning, unless saturated signal was obtained, in which case the acquisition was repeated using 10s imaging time. All data were analyzed using Living Image analysis software (Caliper Lifescience). The region of interest (ROI) for the measured signal was drawn at the tumor site identically for all mice and was set anew for each experiment.

Results

Increasing the affinity of a ζ-CAR does not improve the T cell function

HER-2 specific CARs were cloned into the pMSCV retroviral vector resulting in five CARs with CD3ζ signaling domain (ζ-CARs) with the affinities of their scFv’s between 10^{-7} and 10^{-11} M (Figure 1A), and one CAR with CD3ζ and CD28 signaling domains (28-ζ-CAR) with the affinity of 10^{-9} M (Figure 1A). Following retroviral transduction of mouse splenocytes, the percentage of CAR⁺ CD8⁺ T cells was generally lower for the ζ-CARs (8.5%; SD ± 5%) when compared to the 9-28-ζ-CAR (18.5%; SD ± 13%)
(Figure 1B and Supplementary Fig. S2). Human T cells targeted with these same ζ-CARs responded at a very similar level above the affinity threshold of 1.6x10^{-8} M (20). Similarly, 8-ζ-CAR-Ts responded by secreting more IFNγ compared to 7-ζ-CAR-Ts and levels of IFNγ did not increase with CARs of higher affinity, including the 9-28-ζ-CAR (Figure 1C). CAR-Ts can secrete IL-2 when stimulated through their endogenous CD28 receptor (22) or the chimeric CD28-ζ receptor (19). Accordingly, we found that CAR-Ts engineered with 9-28-ζ but not ζ-CARs secreted IL-2 (Figure 1C).

We next investigated the ability of ζ-CAR-Ts to reject SKOV3 tumors in vivo and whether an increase in scFv affinity influences therapeutic outcome. Rag^-/- mice were subcutaneously (s.c.) injected with 5x10^6 SKOV3 cells. About 3 weeks later when the tumors were 6.6 mm (SD ± 1.1 mm) in average diameter, the mice were treated intravenously (i.v.) with 2x10^6 CAR-Ts transduced with mock (GFP) retrovirus or the different affinity ζ-CARs. Tumors in mice that received 7-ζ-CAR-Ts progressed unimpeded comparable to mock-treated mice (Figure 2 and Table 1). Similarly, ζ-CAR-Ts of the other affinities (including the highest affinity 11-ζ-CAR) did not reject SKOV3 tumors and, if at all, only slightly delayed tumor progression (Figure 2 and Table 1).

**Costimulation by the 28-ζ-CAR leads to rejection of large established tumors**

To determine if addition of an costimulatory CD28 signaling to the CAR molecule would lead to rejection of SKOV3 tumors, tumor-bearing mice were treated with CAR-Ts expressing either 9-ζ- or 9-28-ζ-CAR, which contain the same scFv domain (KD: 1x10^{-9} M) but different signaling domains. As before, tumors grown for ~3 weeks (average tumor diameter 7.1 mm, SD ± 0.4 mm) progressed in mice receiving 9-ζ-CAR-Ts or mock treatment, but were long-term rejected by 9-28-ζ-CAR-Ts (mice remained tumor free 60 days post rejection) (Figure 3A and Table 1). Although both groups received 2x10^6 transduced CD8^+ T cells, due to the different transduction
efficiency, 9-28-ζ-CAR-Ts treated mice received more CAR-Ts (5.6x10^5) than 9-ζ-CAR-Ts treated mice (1.4x10^5). To account for that and exclude that the different therapeutic outcome was due to transferring different numbers of CAR-Ts, tumor-bearing mice were treated with titrated numbers of 9-28-ζ-CAR-Ts. Either 2x10^5 or 5x10^4 CD8^+ T cells were transferred, which equals to 5.6x10^4 or 1.4x10^4 CAR^+ T cells, respectively. In both cases, tumors were again long-term rejected (Figure 3B and Table 1). To further confirm these results, mice with large established tumors (average tumor diameter 10.5 mm, SD ± 1.8 mm) received the same number of CAR^+ T cells; either mock treated or injected with 2x10^6 CAR-Ts with similar percentage of 9-28-ζ- or 9-ζ-CAR^+ cells (8% and 10%, respectively). Once again, 9-28-ζ-CAR-Ts rejected the tumors (n=2), while tumors in mock-treated and 9-ζ-CAR-Ts treated mice progressed (Figure 3C and Table 1).

**CAR-Ts require costimulation to accumulate at the tumor site and persist in vivo**

To visualize the in vivo dynamics of the CAR-Ts associated with tumor rejection compared to CAR-Ts associated with failed therapy, we introduced CARs into T cells derived from renilla luciferase transgenic mice (ChRLuc/OT-1/Rag^−/−) (9) and imaged tumor-bearing mice by bioluminescent in vivo imaging (BLI) at various time points following T cell transfer. The BLI background signal was set at 1x10^5 p/s/cm^2/sr, which is the highest signal emitted at the tumor site by mock-treated mice, probably reflecting the homeostatic expansion of transferred T cells (Figure 4A). Similar to TCR-mediated tumor rejection (9), the presence and persistence of the CAR-T signal was associated with tumor regression as only 9-28-ζ-CAR-Ts accumulated at the tumor site (Figure 4A and B). Typically the signal appeared and reached its peak during the second week post ATT (Figure 4B), where it persisted for 2-3 weeks and then gradually declined (Figure 4A and B). The signal from the in vivo imaging of 9-28-ζ CAR transduced T cells indicate that this population contracted in a fast kinetic following 3 cycles of expansion. This is similar to what we have earlier observed
during the rejection of large established tumors by adoptively transferred TCR transgenic T cells (9). It is likely that, following the expansion, the T cells contracted due to the consumption of the limited amount of the homeostatic cytokines required for T cells persistence. In line with this, a similar pattern has been shown in a study with repeated T cells expansion and contraction during the treatment of 1-week-old B16 melanoma by adoptive T cell therapy (23). Interestingly, in that study, this pattern was replaced by a continuous T cell expansion and persistence pattern when the mice also received IL-15 precomplexed with soluble IL-15 receptor α and IL-21. The last and most substantial contraction phase coincided with tumor rejection. This indicates that during successful adoptive T cell therapy a new cycle of T cell expansion is repeatedly initiated as long as the cognate antigen is available. Since the SKOV3 cells used in this study were transduced with a click beetle luciferase (CBG) expressing retrovirus (21), we confirmed complete tumor rejection by showing that no remaining tumor cells could be detected by BLI (Figure 4C). The values for the ζ-CAR-T imaged-signals did not vary much between the different treatment groups and only a slight increase over background was observed during the BLI time period of 50 days (Figure 4A). By calculating the maximal T cell signal from mock as compared to 9-28-ζ-CAR-T treated mice (9), we estimated that homeostatic expansion contributed to about 5% of Ag-driven proliferation. Decreasing the lower scale to 2x10^4 p/s/cm^2/sr to visualize the homeostatic expansion of the transferred T cells showed that the signal of ζ-CAR-Ts was similar to control treated mice, suggesting these cells were largely ignorant, which was in contrast to the large signal increase of 9-28-ζ-CAR-Ts treated mice (Supplementary Fig. S3).

**Costimulation by the 28-ζ-CAR leads to T cell differentiation and proliferation at the tumor site**
Using BLI, we observed that 9-28-ζ-CAR-Ts expanded in the tumor-bearing mouse and accumulated preferentially at the tumor site (Supplementary Fig. S4). Although BLI allowed us to visualize this accumulation, we could not address the question of whether these cells were also able to proliferate inside the tumor or to evaluate their differentiation status. Since retroviral transduction required antigen-independent T cell activation, 9-ζ-CAR-, 9-28-ζ-CAR- and mock-transduced CAR-Ts contained similar numbers of similarly activated T cells. This was confirmed by the high (hi) expression of CD44 and CD62L (CD44hi, CD62Lhi, Figure 5A), which is typical for memory phenotype. Nevertheless, additional in vivo activation by costimulation was required as only 9-28-ζ-CAR-Ts rejected the tumors while 9-ζ-CAR-Ts did not. Since TCR-mediated tumor rejection favors TEM phenotype (24), we analyzed whether CAR-mediated tumor rejection involved 28-ζ-CAR-Ts differentiation into TEMs. Approximately four weeks post tumor challenge, mice received 2x10^5 CAR+ cells from total 1x10^6 CAR-Ts per mouse (numbers were equalized for all treatments by adding mock cells to CAR transduced T cells). The percentage of CAR+ T cells following transduction was 20% for 9-ζ-CAR-Ts and 40% for 9-28-ζ-CAR-Ts. Similar to the earlier experiments, mice treated with 9-28-ζ-CAR-Ts but not those treated with 9-ζ-CAR-Ts rejected the tumor. By analyzing the tumor infiltrating lymphocytes (TILs) we found that the majority of these cells from the mock- and the 9-ζ-CAR-Ts-treated mice of the CD8+/CD44+ population were CD62Lhi. Interestingly, the majority of the TILs from the 9-28-ζ-CAR-Ts treated mice shifted towards the CD62L low (lo) phenotype, which is typical for TEM cells (Figure 5B). There was no difference in the phenotype of the T cells from the spleens of the mice treated with any of the three T cell therapies, which had similar percentages of the CD62Lhi population (data not shown). To investigate whether 9-28-ζ-CAR-Ts not only accumulated at the tumor site but also proliferated there, we isolated CD8+ cells from the tumors (Figure 5C) and measured the expression of the Ki-67 proliferation marker. Indeed, compared to mock and 9-ζ-CAR-Ts, only 9-28-ζ-CAR-Ts proliferated at the tumor site. This Ki-67
positive population was present in the G2/M phases of the cell cycle, as determined by the PI staining for DNA content (Figure 5C).

**CAR-mediated rejection depends on IFNγR expression on the tumor stroma**

By analyzing the tumors for the cancer cells and stroma cells content, we found that large established SKOV3 tumors contained \(-15\%\) of HER-2\(^{+}\) cancer cells while the other \(85\%\) were stroma cells (Supplementary Fig. S5A). The majority of the stroma cells in the SKOV3 tumors were of non-hematopoietic origin (>\(90\%\) CD45.2 negative, Supplementary Fig. S5A). To investigate whether CAR-mediated tumor rejection requires targeting of the tumor stroma by IFNγ, we treated Rag\(^{-/-}\) and IFNγR\(^{-/-}\)/Rag\(^{-/-}\) mice bearing \(-3\) weeks old SKOV3 tumors (6.6 mm; SD ± 1.5 mm) with mock or 9-28-ζ-CAR-Ts. In Rag\(^{-/-}\) mice, tumors were again rejected following treatment with 9-28-ζ-CAR-Ts (Figure 6A and Table 1). However, following treatment with 9-28-ζ-CAR-Ts, tumors progressed in IFNγR\(^{-/-}\)/Rag\(^{-/-}\) mice at a comparable kinetic to that seen in mock-treated mice (Figure 6A and Table 1).

In the current settings, IFNγ secreted by the transferred T cells could have contributed to tumor eradication either by direct stroma destruction (10,31) or indirectly by activating NK cells and M1 macrophages (21,25). To answer this question, we compared the NK cells and macrophages infiltration in the tumors of mock, 9-ζ-CAR-T and 9-28-ζ-CAR-T treated tumor-bearing mice. Tumors from the mice that received 9-28-ζ-CAR-Ts had a high percentage of infiltrating NK cells (30\%) compared to tumors from 9-ζ-CAR-T (10\%) and mock (4\%) treated mice (Figure 6B). Tumors isolated from 9-ζ-CAR-T treated mice contained about 2x more NK cells than tumors from mock treated mice (Figure 6B), which is not surprising since we showed that 9-ζ-CAR-Ts secrete IFNγ upon antigen recognition. The numbers of tumor infiltrating macrophages (F4/80/CD11b double positive) did not vary much between 9-28-ζ-\(^{-},\ 9-ζ-CAR-T\) and mock treated mice (Figure 6C).
Nevertheless, macrophages in tumors from 9-28-ζ-CAR-T treated mice had a marked increase in MHC class II expression (80%) which is typical for M1 macrophage population, while the percentages were much lower for 9-ζ-CAR-T (43%) and mock (28%) treated mice (Figure 6C). These findings indicate that the IFNγ secreted by 9-28-ζ-CAR-Ts activated NK cells and M1 macrophages. To investigate the role of NK cell activation in tumor rejection, we performed an in vivo NK cell depleting experiment. Tumor bearing mice received a-NK 1.1 antibody or isotype (iso) control weekly over the period of 85 days (starting two days before ATT) which depleted the NK cells in the blood (Supplementary Fig. S5B). Mock treated mice did not receive any additional treatment and tumors progressed (Figure 6D). Mice that were treated with a-NK 1.1 antibody and isotype control received 9-28-ζ-CAR-Ts, and during the observation time of 82 days post ATT majority of the tumors were rejected for both groups (2/3 for isotype control and 4/5 for NK depleted) (Figure 6D). This indicates that NK cells were not necessary for the CAR-mediated tumor rejection.

Discussion

Our study showed for the first time that CAR-Ts were able to reject large solid tumors exclusively by CAR-mediated CD8⁺ T cell effector function and independent of CD4⁺ T cell or B cell contribution. Costimulation provided by the CD28 signaling domain of the 9-28-ζ-CAR was essential for tumor rejection in our model and could not be compensated for by increasing the affinity of the scFv domain of the ζ-CARs. The inability of ζ-CAR-Ts to secrete IL-2 may have contributed to their failure to proliferate, differentiate into TEM and accumulate at the tumor site to mediate HER-2-specific tumor rejection. Another reason for therapy failure might have been the tumor burden; perhaps ζ-CAR-Ts would have been more effective against smaller tumors (26).
Both antigen-dependent and -independent mechanisms can contribute to stroma destruction as a requirement for cancer eradication (27). Previous studies of TCR-mediated ATT consistently reported that tumor stroma targeting was critical to prevent tumor recurrence and that T cell-produced IFN\(\gamma\) needed to act on the tumor stroma (8,11). However, likely due to the use of different experimental models, different mechanisms were suggested to explain this. When using a surrogate antigen expressed at a high level, antigen cross-presentation by stroma cells was essential for bystander elimination of antigen loss variants (7,8), while targeting a CDA (like SV40 large T antigen) did not require antigen cross-presentation for tumor eradication in a H-2 mismatched host (10,11). Excluding that cross-dressing by the peptide-MHC (28) could have contributed to stroma recognition in the H-2 mismatched host, it appeared but was not formally proven that antigen recognition only on the cancer cells was sufficient for tumor rejection. This could have resulted from the induction of IFN\(\gamma\) production by the T cells, which then acted on stroma cells in an antigen-independent fashion either by direct stroma destruction or indirectly by activating the non T cell immune compartment (10,11,29,30). We proved the initial assumption in our current study because CAR-Ts recognized HER-2 exclusively on the cancer cells but not tumor stroma, yet IFN\(\gamma\) responsiveness by the stroma was essential for tumor rejection. There was a correlation between increase in the M1 macrophage numbers and tumor rejection in our model, however, it is not clear whether the macrophages directly contributed to tumor rejection, or whether simply the increase was due to higher number of T cells secreting IFN\(\gamma\) in the tumors. Similarly, IFN\(\gamma\) led to NK cell activation, but despite the increased numbers of NK cell infiltrates in tumors of 28-\(\zeta\)-CAR-T treated mice, the CAR-mediated tumor rejection was not dependent on NK cells. In accordance with our previous studies (10,31), it is possible that the mechanism of IFN\(\gamma\) acting on tumor stroma has a direct effect involving destruction of tumor vasculature. However, we cannot completely exclude that direct targeting of some stroma cells may have been mediated by recognition of
acquired tumor-derived microvesicles containing HER-2, since such acquisition was observed for some surface receptors (32).

Due to species-specific binding, the IFNγ secreted by the mouse T cells could only act on the tumor stroma but not on the cancer cells, which might explain the prolonged rejection time required in our model. Simultaneous cancer and stroma cell targeting would have probably accelerated tumor rejection, as is the case in other models where both tumor compartments were targeted by IFNγ (7,9,10). Furthermore, the inability of 9-28-ζ-CAR-Ts therapy to induce initial tumor regression in IFNγR−/−/Rag− mice could be attributed to this specific setting, in which both cancer and stroma cells were not responsive to IFNγ (11).

Although targeting stroma cells by IFNγ was essential for tumor rejection in our model, we cannot exclude that stroma cell targeting would have been dispensable in a setting where also cancer cells responded to IFNγ. However, in the cases when human CAR-Ts were used for therapy and cancer cells responded to IFNγ, established tumors could not be completely rejected (3,17), further implying at the relevance of IFNγ-stroma cell targeting for tumor rejection. Therefore, it will be important in future studies to elucidate the relative contribution of antigen-dependent (7,8) and -independent (10,11) destruction of tumor stroma and whether our data are related to targeting a CDA.

Despite the effectiveness of tumor rejection by 9-28-ζ-CAR, we do not suggest using HER-2-CARs in the clinic, because we did not address potential toxicity in regard to HER-2 expression on normal cells. However, our data are clinically relevant because tumor-specific antigens accessible for CARs have been described (15,16) and will be evaluated for clinical use (33). Taken together, our results show that antigen-independent tumor stroma destruction is required for CAR-mediated cancer eradication.
Acknowledgments

The authors thank M. Hensel and S. Kupsch for technical assistance, and Rosa Karlić for the statistical analysis.

Authors' Contributions

J.C., T.B., A.T. and J.L. designed research; A.T., J.L., L.W., C.P., A.K. and J.C. performed research; M.C. and H.A. provided reagents; A.T., J.L., L.W., J.C. and T.B. analyzed data; A.T., H.A., T. B. and J.C. wrote the manuscript.

Grant Support

This work was supported by the Deutsche Krebshilfe (J.C. and T. B.) and by Deutsche Forschungsgemeinschaft Transregio-Sonderforschungsbereich TR36 (J. C. and T. B.).
References


29. Schüler T, Blankenstein T. Cutting edge: CD8+ effector T cells reject tumors


Figure Legends

Figure 1. Mouse T cells express the HER-2-specific CARs and secrete IFNγ when stimulated with SKOV3 target cells, but only recognition by 9-28-ζ-CAR leads to production of IL-2. A, HER-2-specific ζ-CAR constructs of five different affinities (KD: 3.2×10⁻⁷-1.5×10⁻¹¹ M) and HER-2-specific 28-ζ-CAR construct of intermediate affinity
(KD; 1x10^{-9}) were cloned into pMSCV vector. The resulting retroviral vectors were designated as pMSCV-7-ζ-CAR for the lowest affinity (KD: 3.2x10^{-7} M), pMSCV-8-ζ-CAR for the wild type construct (KD: 1.6x10^{-8} M), followed by pMSCV-9-ζ-, pMSCV-10-ζ- and pMSCV-11-ζ-CAR constructs with the increasing affinities of KD: 1x10^{-9}, 1.2x10^{-10} and 1.5x10^{-11} M, respectively. pMSCV-9-28-ζ-CAR is the resulting retroviral vector for the dual signaling CAR with intermediate affinity of KD: 1x10^{-9} M. B, splenocytes derived from ChRLuc/OT-1/Rag^{-/-} mice were transduced with different CAR constructs. Untransduced (-) and CAR transduced T cells were stained with α-CD8 and α-hIgG Abs and analyzed by flow cytometry. C, splenocytes derived from OT-1/Rag^{-/-} mice were transduced with different ζ-CARS and with the 9-28-ζ-CAR. The average expression for ζ-CARS was 6% (SD ± 3%) and 5% for the 9-28-ζ-CAR. Mock and CAR transduced T cells were cocultured with titrated numbers of SKOV3 cells for 24h and levels of secreted IFNγ and IL-2 were measured by ELISA. Data represent mean values of triplicates and one representative experiment of two is shown.

**Figure 2.** Engineering T cells with high affinity ζ-CARS does not lead to tumor rejection. Rag^{-/-} mice were challenged with 5x10^6 SKOV3 cells. Approximately three weeks post tumor inoculation, tumor-bearing mice were treated with 2x10^6 ChRLuc/OT-1/Rag^{-/-} ζ-CAR-Ts or mock T cells. The percentage of CAR expression for 7-, 8-, 9- 10- and 11-ζ-CAR was 5, 8, 7, 7 and 5%, respectively. Indicated is mean tumor diameter over the time period of the experiment for each mouse (each line), n=2 for mock, n=3 for 7-, 8- 10- and 11-ζ-CAR, and n=4 for 9-ζ-CAR. Each line represents a mean tumor diameter in a single mouse. Shown is one representative experiment out of two.

**Figure 3.** CAR-Ts expressing 9-28-ζ-CAR reject large established SKOV3 tumors in Rag^{-/-} mice. A, Rag^{-/-} mice bearing three weeks old SKOV3 tumors received 2x10^6
CAR-Ts derived from ChRLuc/OT-1/Rag^- expressing CARs of the same affinity but different signaling molecules (9-28-ζ-CAR (n= 3), 9-ζ-CAR (n= 3)) or mock transduced (n= 2). The percentage of CAR^+ T cells was 28% and 7% for 9-28-ζ-CAR and 9-ζ-CAR, respectively. B, depicted are mice (n= 3 for each treatment) from the same experiment as in (A), which were treated with lower numbers of 9-28-ζ-CAR-Ts (2x10^5 or 5x10^4). In total three experiments were performed for ATT with 2x10^6 T cells, two with 2x10^5 and one with 5x10^4 T cells. C, four weeks post SKOV3 tumor challenge Rag^- mice were treated with 2x10^5 CAR-Ts (ChRLuc/OT-1/Rag^-) expressing 9-ζ-CAR, 9-28-ζ-CAR or mock T cells (n= 2 for each treatment). The percentage of CAR^+ cells was similar for the 9-ζ- and 9-28-ζ-CAR-Ts (10% and 8%, respectively). Each line represents a mean tumor diameter of a single mouse. Data are representative of 2 independently performed experiments.

**Figure 4.** CAR-Ts expressing ζ-CAR fail to expand and to accumulate specifically at the tumor site while 28-ζ CAR-Ts do. A, T cell signal at the tumor site of the adoptively transferred CAR-Ts (derived from ChRLuc/OT-1/Rag^- mice) was followed over time. The shaded box represents the background signal, which was set to 1x10^5 photon/s/cm^2/steradian. Each line represents the signal emitted at the tumor site from a single mouse (n=2 for mock, n=3 for the all five ζ-CARs, n=4 for the 9-28-ζ-CAR). B, T cell signal for one representative mouse is shown on different indicated days post ATT for mice receiving mock, 9-ζ- or 9-28-ζ-CAR-Ts. C, shown are mice with tumor rejection imaged to detect FLuc signal emitted by the tumor cells. Data are representative of 2 independently performed experiments.

**Figure 5.** 9-28-ζ-CAR-Ts differentiate into effector memory T cells and proliferate at the tumor site. A, splenocytes from ChRLuc/OT-1/Rag^- mice were either left untreated (naïve) or were transduced with mock, 9-ζ-CAR or 9-28-ζ-CAR retroviruses. Two days after last transduction, cells were stained with a-CD3, a-CD44
and a-CD62L antibodies and analyzed by flow cytometry. Shown are CD3 gated cells. B, single tumor cells (day 16 post ATT) were labeled with a-CD8, a-CD44 and a-CD62L antibodies. Shown are CD8/CD44 gated cells of one representative tumor sample per group out of two. C, shown are CD8+ cells that were MACS sorted with 85% purity from two pooled tumor samples for each treatment (mock, 9-ζ-CAR or 9-28-ζ-CAR) and labeled with PI and a-Ki-67 antibody (day 31 post ATT).

**Figure 6.** 9-28-ζ-CAR-mediated rejection of SKOV3 tumors requires IFNγR expression by the tumor stroma, and is NK cell independent. A, Rag−/− and IFNγR−/−/Rag−/− mice were challenged with SKOV3 cells. Approximately three weeks post tumor challenge, mice received OT-1/Rag−/− 9-28-ζ-CAR-Ts (n=4 for A, B and C) or mock T cells (n=2 for A, B and C). A, indicated are mean tumor diameters over time of individual mice from one representative experiment out of two. B, shown are single tumor cells labeled with a-NK 1.1 and a-CD49b (DX5) Ab gated on the lymphocytes for one representative out of two mice analyzed for mock treated tumors and one out of total four for 9-ζ-CAR and 9-28-ζ-CAR treated tumors (combined from days 8 and 16 post ATT). C, single cell suspensions of tumors from mice receiving mock T cells, 9-ζ-CAR-Ts or 9-28-ζ-CAR-Ts were labeled with a-F4/80, a-CD11b and a-IA-IE Ab. Data are gated on live cells (top panels). Histograms indicate MHC class II expression on F4/80/CD11b double positive cells. Same numbers of tumor samples per treatment are shown as in B. D, Approximately four weeks post tumor challenge mice received 2x10^6 9-28-ζ-CAR-Ts (40% CAR+). Two days before ATT mice were treated with either a-NK 1.1 (n=5) or isotype control (iso) (n=3) Ab, which was followed by weekly Ab administration throughout the duration of the experiment. Mock treated mice (n=2) did not receive Ab treatment. Indicated are mean tumor diameters of individual mice over time from a single experiment.
### Tables

<table>
<thead>
<tr>
<th>construct</th>
<th>recipient</th>
<th>T cell #</th>
<th>rejection</th>
<th># of experiments</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-ζ-CAR</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>0/6</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>8-ζ-CAR</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>0/6</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>9-ζ-CAR</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>0/13</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>10-ζ-CAR</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>0/6</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>11-ζ-CAR</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>0/6</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>mock</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>0/15</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>IFNγR²/²/Rag</td>
<td>2x10⁶</td>
<td>0/4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>9-28-ζ-</td>
<td>Rag</td>
<td>2x10⁶</td>
<td>21/21</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>CAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>----</td>
<td>----</td>
<td>----</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2x10⁵</td>
<td>7/7</td>
<td>2</td>
<td>0.000006</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5x10⁴</td>
<td>3/3</td>
<td>1</td>
<td>0.001225</td>
<td></td>
</tr>
<tr>
<td>IFNγR⁻/Rag</td>
<td>2x10⁶</td>
<td>0/10</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1.** Total mice numbers. Indicated are numbers of mice that rejected the tumors from total mice in all experiments from different constructs and conditions. *P* value was calculated in comparison to mock treated group using Fisher’s exact test.
**Figure 1**

A. Diagram of MSCV-ζ-CAR and pMSCV-28-ζ-CAR constructs showing KD and constructs.

B. Flow cytometry analysis showing expression of CD8 and Human Ig for different constructs.

C. Graphs showing IFNγ and IL-2 production by SKOV3 cells with different constructs.
Figure 2
Figure 3

A  
- mock
- 9-ζ-CAR (2x10⁶)
- 9-28-ζ-CAR (2x10⁶)

B  
- 9-28-ζ-CAR (2x10⁵)
- 9-28-ζ-CAR (5x10⁴)

C  
- mock
- 9-ζ-CAR
- 9-28-ζ-CAR

Mean Tumor Diameter (mm)

Days Post ATT
Figure 4

A. Average Radiance (p/s/cm²/sr) over Days post ATT for different CAR variants.

B. T cell infiltration over Days post ATT for mock, 7-ζ-CAR, 8-ζ-CAR, 9-ζ-CAR, 10-ζ-CAR, 11-ζ-CAR, and 9-28-ζ-CAR.

C. Tumor growth over Days post ATT for mock, 9-ζ-CAR, and 9-28-ζ-CAR.

Note: Images and data are illustrative and not actual scientific results.
Figure 5
Figure 6
Efficacy of CAR T cell therapy in large tumors relies upon stromal targeting by IFN γ

Ana Textor, Joanna Listopad, Lara Le Wührmann, et al.

Cancer Res  Published OnlineFirst October 8, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-0079

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/10/08/0008-5472.CAN-14-0079.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.